The Environment for Life Sciences Dealmaking and How to Gain Leverage in Negotiations



Kristian Werling said that 2017 was “a very interesting year for life science dealmaking. There was an absence of the so-called mega-deals that we’ve seen in a few recent years … But there were a number of deals in the middle market – in the billion and a half to two billion dollars range – so overall it was a really productive year for companies looking to build the product pipeline.”